MovDisordV3, France, Analysis, bibRecord, 000616

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

Identifieur interne : 000616 ( France/Analysis ); précédent : 000615; suivant : 000617

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

Auteurs : Jean-Louis Montastruc [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; André Rascol [France]

Source :

Movement Disorders [ 0885-3185 ] ; 1995-05.

RBID : ISTEX:794B65EFAA59534089F840B4DFED836EB05AD735

Descripteurs français

Pascal (Inist)
- Antidépresseur, Etude préalable, Fluoxétine, Homme, Parkinson maladie, Parkinsonien syndrome, Toxicité.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antidepressant agent, Drug Therapy, Combination, Female, Fluoxetine (administration & dosage), Fluoxetine (adverse effects), Human, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Parkinson disease, Parkinsonian syndrome, Pilot Projects, Previous study, Prospective Studies, Toxicity, Treatment Outcome.
MESH :
- chemical , administration & dosage : Fluoxetine, Levodopa.
- chemical , adverse effects : Fluoxetine, Levodopa.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Secondary.
- drug effects : Neurologic Examination.
- drug therapy : Parkinson Disease.
- Aged, Drug Therapy, Combination, Female, Humans, Male, Pilot Projects, Prospective Studies, Treatment Outcome.

Url:

https://api.istex.fr/document/794B65EFAA59534089F840B4DFED836EB05AD735/fulltext/pdf

DOI: 10.1002/mds.870100325

Affiliations:

Links to Exploration step

ISTEX:794B65EFAA59534089F840B4DFED836EB05AD735

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does fluoxetine aggravate Parkinson's disease? A pilot prospective study</title>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
<author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:794B65EFAA59534089F840B4DFED836EB05AD735</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100325</idno>
<idno type="url">https://api.istex.fr/document/794B65EFAA59534089F840B4DFED836EB05AD735/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003A01</idno>
<idno type="wicri:Area/Istex/Curation">003A01</idno>
<idno type="wicri:Area/Istex/Checkpoint">003D46</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Montastruc J:does:fluoxetine:aggravate</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:7651460</idno>
<idno type="wicri:Area/PubMed/Corpus">004973</idno>
<idno type="wicri:Area/PubMed/Curation">004973</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004993</idno>
<idno type="wicri:Area/Ncbi/Merge">004739</idno>
<idno type="wicri:Area/Ncbi/Curation">004739</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004739</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Montastruc J:does:fluoxetine:aggravate</idno>
<idno type="wicri:Area/Main/Merge">008A77</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:95-0362305</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003502</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003322</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003507</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Montastruc J:does:fluoxetine:aggravate</idno>
<idno type="wicri:Area/Main/Merge">008C04</idno>
<idno type="wicri:Area/Main/Curation">005915</idno>
<idno type="wicri:Area/Main/Exploration">005915</idno>
<idno type="wicri:Area/France/Extraction">000616</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Does fluoxetine aggravate Parkinson's disease? A pilot prospective study</title>
<author><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="région" nuts="2">Midi-Pyrénées</region>
</placeName>
<wicri:orgArea>Department of Medical and Clinical Pharmacology, Inserm U317, and Centre Midi‐Pyrénées, de Pharmacovigilance et d'Informations, sur le Médicament, Centre Hospitalier Universitire, Faculté de Médecine</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="région" nuts="2">Midi-Pyrénées</region>
</placeName>
<wicri:orgArea>Department of Neurology, Centre Hospitalier Universitaire, Hôpital Rangueil</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Marseille</settlement>
<region type="région" nuts="2">Provence-Alpes-Côte d'Azur</region>
</placeName>
<wicri:orgArea>Department of Medical and Clinical Pharmacology, Faculté de Médecine</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="région" nuts="2">Midi-Pyrénées</region>
</placeName>
<wicri:orgArea>Department of Medical and Clinical Pharmacology, Inserm U317, and Centre Midi‐Pyrénées, de Pharmacovigilance et d'Informations, sur le Médicament, Centre Hospitalier Universitire, Faculté de Médecine</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country>France</country>
<placeName><settlement type="city">Toulouse</settlement>
<region type="région" nuts="2">Midi-Pyrénées</region>
</placeName>
<wicri:orgArea>Department of Medical and Clinical Pharmacology, Inserm U317, and Centre Midi‐Pyrénées, de Pharmacovigilance et d'Informations, sur le Médicament, Centre Hospitalier Universitire, Faculté de Médecine</wicri:orgArea>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Midi-Pyrénées</region>
</placeName>
<orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName>
<orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName>
</affiliation>
</author>
<author><name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurology, Centre Hospitalier Universitaire, Hôpital Purpan, Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-05">1995-05</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="355">355</biblScope>
<biblScope unit="page" to="357">357</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">794B65EFAA59534089F840B4DFED836EB05AD735</idno>
<idno type="DOI">10.1002/mds.870100325</idno>
<idno type="ArticleID">MDS870100325</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antidepressant agent</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Fluoxetine (administration & dosage)</term>
<term>Fluoxetine (adverse effects)</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (diagnosis)</term>
<term>Parkinson disease</term>
<term>Parkinsonian syndrome</term>
<term>Pilot Projects</term>
<term>Previous study</term>
<term>Prospective Studies</term>
<term>Toxicity</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fluoxetine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Fluoxetine</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Pilot Projects</term>
<term>Prospective Studies</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antidépresseur</term>
<term>Etude préalable</term>
<term>Fluoxétine</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Parkinsonien syndrome</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Midi-Pyrénées</li>
<li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Marseille</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université Toulouse III - Paul Sabatier</li>
<li>Université de Toulouse</li>
</orgName>
</list>
<tree><country name="France"><region name="Midi-Pyrénées"><name sortKey="Montastruc, Jean Ouis" sort="Montastruc, Jean Ouis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</region>
<name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name>
<name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name>
<name sortKey="Rascol, Andre" sort="Rascol, Andre" uniqKey="Rascol A" first="André" last="Rascol">André Rascol</name>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000616 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000616 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     ISTEX:794B65EFAA59534089F840B4DFED836EB05AD735
   |texte=   Does fluoxetine aggravate Parkinson's disease? A pilot prospective study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.